摘要
目的探讨冠心病患者血浆中单核细胞趋化蛋白-1(MCP-1)水平的影响因素及不同类型冠心病患者血浆中MCP-1表达水平。方法检测急性心肌梗死(AMI)(n=49)、不稳定型心绞痛(UA)(n=49)、稳定型心绞痛和(或)陈旧性心肌梗死(AP+OMI)(n=49)患者及健康对照者(n=49)血浆中MCP-1水平,并同时检测147例冠心病患者血清高敏C-反应蛋白(hs-CRP)水平。结果①血浆中MCP-1水平和hs-CRP呈正相关(r=0.447,P<0.01);MCP-1水平与收缩压(SBP)、体质量指数(BMI)、脂蛋白(a)[LP(a)]、空腹血糖(FBG)呈正相关(r=0.211,P=0.01;r=0.222,P=0.008;r=0.271,P=0.001;r=0.355,P<0.01);MCP-1水平与高密度脂蛋白胆固醇(HDL-C)、载脂蛋白AⅠ(ApoAⅠ)呈负相关(r=-0.227,P=0.009;r=0.268,P=0.002)。②AMI组、UA组、AP+OMI组与对照组比较,血浆中MCP-1水平逐渐降低(1.83±0.36,1.68±0.31,1.61±0.17,1.59±0.59),但只有AMI组与对照组之间比较差异有统计学意义(P=0.001)。结论血浆MCP-1水平与冠心病危险因素相关,提示MCP-1可能作为指示冠心病发生、发展的一个生化指标。
Objective To investigate the influencing factors of plasma MCP-1 levels in patients with coronary artery disease (CAD) and the palsma monocyte chemoattractant protein-1 ( MCP-1 ) expression levels in different types of CAD. Methods Patients with confirmed acute myocardial infarction(AMI) (n = 49 ), unstable angina(UA) (n = 49), stable angina and/or old myocardial infarction(AP ± OMI) (n =49) were recruited in the study. Forty-nine healthy controls were also included. The concentration of plasma MCP-1 was measured by enzyme-linked immunoabsorbent assay(ELISA) and the levels of high-sensitivity C- reactive protein(hs-CRP) were detected. Results ①The levels of MCP-1 were positively correlated with hs-CRP, systolic blood pressure (SBP), body mass index (BMI), lipoprotein (a) [ LP (a) ], fasting blood glucose (FBG) ( r = 0. 447, P 〈 0.01 ; r = 0. 211,P = 0.01 ;r = 0. 222,P = 0. 008;r = 0.271,P = 0. 001 ;r = 0. 355,P 〈 0.01 ). The levels of MCP-1 were negatively correlated with high-density lipoprotein-cholesterol ( HDL-C), apoproteinA I ( ApoA I ) ( r = - 0. 227, P = 0. 009 ; r = 0. 268, P = 0. 002).②The levels of MCP-1 in the four groups ( AMI group, UA group, AP + OMI group and control group) gradually decreased( 1.83 ± 0.36,1.68 ± 0.31,1.61 ± 0.17,1.59 ± 0.59), but only the difference between the AMI group and the control group had significant difference ( P = 0. 001 ). Conclusion The plasma level of MCP-1 is correlated with some conventional CAD risk factors. MCP-1 may be a biochemical marker for indicating the development of CAD.
出处
《临床医学》
CAS
2014年第4期6-8,共3页
Clinical Medicine